HC Wainwright & Co. Maintains Buy on Alimera Sciences, Lowers Price Target to $5
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Yi Chen maintains a Buy rating on Alimera Sciences (NASDAQ:ALIM) but lowers the price target from $9 to $5.
May 19, 2023 | 10:20 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
HC Wainwright & Co. maintains a Buy rating on Alimera Sciences but lowers the price target from $9 to $5.
The news directly mentions Alimera Sciences (ALIM) and the lowered price target by HC Wainwright & Co. While the Buy rating is maintained, the reduced price target may have a neutral impact on the stock price in the short term as it indicates a lower expected return for investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100